Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production

被引:34
|
作者
Kolling, Glynis L. [1 ]
Wu, Martin [2 ]
Warren, Cirle A. [1 ]
Durmaz, Evelyn [3 ]
Klaenhammer, Todd R. [3 ]
Timko, Michael P.
Guerrant, Richard L. [1 ]
机构
[1] Univ Virginia, Dept Internal Med, Div Infect Dis, Charlottesville, VA 22904 USA
[2] Univ Virginia, Dept Biol, Charlottesville, VA USA
[3] North Carolina State Univ, Dept Food Bioproc & Nutr Sci, Raleigh, NC USA
基金
美国国家卫生研究院;
关键词
Clostridium difficile; Streptococcus thermophilus; probiotic; mouse model;
D O I
10.4161/gmic.21757
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Antibiotic treatment to treat specific infections has the potential to effectively target the offending microbe as well as other microbes that colonize sites within a host. Antibiotic-associated diarrhea (AAD) is a classic example resulting from disruption of host microbial communities; 20% of patients with AAD are likely to become colonized with Clostridium difficile. Restoration of a "normal" microbial community within the host using probiotic bacteria is one approach to circumvent AAD and C. difficile infection. The goals of this study were to assess the interactions between Streptococcus thermophilus, a potential probiotic organism and C. difficile using both in vitro and in vivo systems. Exposure of C. difficile to filtered supernatants from S. thermophilus showed a dose-dependent, bactericidal effect due to lactic acid. Additional studies show that levels of lactic acid (10 mM) that did not inhibit bacterial growth had the potential to decrease tcdA expression and TcdA release into the extracellular milieu. In vivo, treatment with viable S. thermophilus significantly increased luminal levels of lactate in the cecum compared with UV-irradiated S. thermophilus. In the context of infection with C. difficile, mice treated with viable S. thermophilus exhibited 46% less weight loss compared with untreated controls; moreover, less pathology, diarrhea, and lower detectable toxin levels in cecal contents were evident more often in S. thermophillus treated mice. A significant, inverse correlation (Spearman r = -0.942, p = 0.017) between the levels of luminal lactate and abundance of C. difficile were noted suggesting that lactate produced by S. thermophilus is a factor impacting the progression of C. difficile infection in the murine system.
引用
收藏
页码:523 / 529
页数:7
相关论文
共 50 条
  • [1] Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production (vol 3, pg 523, 2012)
    Kolling, Glynis L.
    Wu, Martin
    Warren, Cirle A.
    Durmaz, Evelyn
    Klaenhammer, Todd R.
    Timko, Michael P.
    Guerrant, Richard L.
    GUT MICROBES, 2013, 4 (02) : 175 - 175
  • [2] Effect of phage infection on toxin production by Clostridium difficile
    Goh, S
    Chang, BJ
    Riley, TV
    JOURNAL OF MEDICAL MICROBIOLOGY, 2005, 54 (02) : 129 - 135
  • [3] Effects of Surotomycin on Clostridium difficile Viability and Toxin Production In Vitro
    Bouillaut, Laurent
    McBride, Shonna
    Sorg, Joseph A.
    Schmidt, Diane J.
    Suarez, Jose M.
    Tzipori, Saul
    Mascio, Carmela
    Chesnel, Laurent
    Sonenshein, A. L.
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (07) : 4199 - 4205
  • [4] Measurement of toxin production by Clostridium difficile
    Freeman, J
    Fawley, W
    Baines, S
    Wilcox, M
    LANCET, 2006, 367 (9515): : 982 - 983
  • [5] Control of Clostridium difficile toxin production by biotin
    Yamakawa, K
    Karasawa, T
    Nakamura, S
    JAPANESE JOURNAL OF MEDICAL SCIENCE & BIOLOGY, 1996, 49 (5-6): : 269 - 269
  • [6] Fidaxomicin inhibits toxin production in Clostridium difficile
    Babakhani, Farah
    Bouillaut, Laurent
    Sears, Pamela
    Sims, Carlee
    Gomez, Abraham
    Sonenshein, Abraham L.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (03) : 515 - 522
  • [7] Measurement of toxin production by Clostridium difficile -: Reply
    Warny, M
    Pepin, J
    Fang, AQ
    Killgore, G
    McDonald, LC
    LANCET, 2006, 367 (9515): : 983 - 984
  • [8] Fidaxomicin reduces early toxin A and B production and sporulation in Clostridium difficile in vitro
    Aldape, Michael J.
    Packham, Aaron E.
    Heeney, Dustin D.
    Rice, Savannah N.
    Bryant, Amy E.
    Stevens, Dennis L.
    JOURNAL OF MEDICAL MICROBIOLOGY, 2017, 66 (10) : 1393 - 1399
  • [9] SPOROGENESIS AND TOXIN-A PRODUCTION BY CLOSTRIDIUM-DIFFICILE
    KETLEY, JM
    MITCHELL, TJ
    HASLAM, SC
    STEPHEN, J
    CANDY, DCA
    BURDON, DW
    JOURNAL OF MEDICAL MICROBIOLOGY, 1986, 22 (01) : 33 - 38
  • [10] Risk factors for Clostridium difficile colonisation and toxin production
    Starr, JM
    Martin, H
    McCoubrey, J
    Gibson, G
    Poxton, IR
    AGE AND AGEING, 2003, 32 (06) : 657 - 660